SciClone Pharmaceuticals (Holdings) Limited

SciClone Pharmaceuticals (Holdings) Limitedverified

6600.HK

Price:

$18.72

Market Cap:

$10.67B

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; an...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2021-03-03

Stock Exchange

HKSE

Ticker

6600.HK

The PE Ratio as of December 2025 (TTM) for SciClone Pharmaceuticals (Holdings) Limited (6600.HK) is 10.12

According to SciClone Pharmaceuticals (Holdings) Limited’s latest financial reports and current stock price. The company's current PE Ratio is 10.12. This represents a change of 67.23% compared to the average of 6.05 of the last 4 quarters.

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) Historical PE Ratio (quarterly & annually)

How has 6600.HK PE Ratio performed in the past?

The mean historical PE Ratio of SciClone Pharmaceuticals (Holdings) Limited over the last ten years is 61.27. The current 10.12 PE Ratio has changed 1.55% with respect to the historical average. Over the past ten years (40 quarters), 6600.HK's PE Ratio was at its highest in in the December 2020 quarter at 41.92. The PE Ratio was at its lowest in in the June 2021 quarter at 0.

Quarterly (TTM)
Annual

Average

61.27

Median

6.34

Minimum

0

Maximum

541.66

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) PE Ratio by Quarter and Year

Discovering the peaks and valleys of SciClone Pharmaceuticals (Holdings) Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = 541.66

Minimum Annual Increase = 0%

Minimum Annual PE Ratio = 0

Quarterly (TTM)
Annual
YearPE RatioChange
20236.9119.95%
20225.7610.30%
20215.22-62.92%
202014.08-23.20%
201918.34-11.38%
201820.70-96.18%
2017541.66Infinity%
201600%
201500%
201400%

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) Average PE Ratio

How has 6600.HK PE Ratio performed in the past?

The current PE Ratio of SciClone Pharmaceuticals (Holdings) Limited (6600.HK) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

5.97

5-year avg

10.06

10-year avg

61.27

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) PE Ratio vs. Peers

How is 6600.HK’s PE Ratio compared to its peers?

SciClone Pharmaceuticals (Holdings) Limited’s PE Ratio is less than YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (25.96), less than Lansen Pharmaceutical Holdings Limited (11.26), greater than New Horizon Health Limited (-67.28), less than Hang Chi Holdings Limited (11.79), greater than China Evergrande New Energy Vehicle Group Limited (-0.14), less than Mega Genomics Limited (45.89), greater than IntelliCentrics Global Holdings Ltd. (-26.74), greater than Aidigong Maternal & Child Health Limited (-0.92), greater than Pine Care Group Limited (-29.25), less than Honliv Healthcare Management Group Company Limited (82.28),

Build a custom stock screener for SciClone Pharmaceuticals (Holdings) Limited (6600.HK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SciClone Pharmaceuticals (Holdings) Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like SciClone Pharmaceuticals (Holdings) Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is SciClone Pharmaceuticals (Holdings) Limited's PE Ratio?

How is the PE Ratio calculated for SciClone Pharmaceuticals (Holdings) Limited (6600.HK)?

What is the highest PE Ratio for SciClone Pharmaceuticals (Holdings) Limited (6600.HK)?

What is the 3-year average PE Ratio for SciClone Pharmaceuticals (Holdings) Limited (6600.HK)?

What is the 5-year average PE Ratio for SciClone Pharmaceuticals (Holdings) Limited (6600.HK)?

How does the current PE Ratio for SciClone Pharmaceuticals (Holdings) Limited (6600.HK) compare to its historical average?